🔎 Trials Near Me

Akèy › Enfeksyon COVID-19 ak Koronaviris › Texas › Houston

Etid klinik pou Enfeksyon COVID-19 ak Koronaviris nan Houston, TX

5 etid pou Enfeksyon COVID-19 ak Koronaviris ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study of COVID-19 Vaccine(s) in Children and Adults

Ap rekriteFaz 3Volontè an sante akeyi
  • DM Clinical Research-Cyfair, Houston
Laj 5 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07798648

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Ap rekriteFaz 3
  • Cockrell Center for Advanced Therapeutics, Houston
  • Houston Methodist - Transplant Center, Houston
  • Houston Methodist Hospital, Houston
  • ak 4 plis
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07013474

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Ap rekriteFaz 3
  • Memorial Hermann Hospital TMC, Houston
  • The University of Texas Health Science Center at Houston, Houston
  • UT Physicians, Houston
  • ak 4 plis
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06679140

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Ap rekriteFaz 3
  • Baylor College of Medicine, Houston
  • MD Anderson, Houston
Tout laj · Tout sèks · Mizajou Jun 23, 2026 · NCT03808922

Clazakizumab vs. Placebo - COVID-19 Infection

Ap rekriteFaz 2
  • Houston Methodist Hospital, Houston
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2020 · NCT04494724

Etid Enfeksyon COVID-19 ak Koronaviris nan lòt vil

Lòt etid nan Houston

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.